The impact of eligibility for maintenance immunotherapy on prognosis in patients with unresectable or metastatic urothelial carcinoma.

Kai OzakiShingo HatakeyamaToshikazu TanakaDaisuke NoroNoriko TokuiHirotaka HoriguchiYoshiharu OkuyamaNaoki FujitaTeppei OkamotoAkiko OkamotoYuichiro SuzukiHayato YamamotoTakahiro YoneyamaYasuhiro HashimotoChikara Ohyama

Published in: BJUI compass (2021)

We observed 38% of the trial eligible population. Overall survival was significantly different between the trial eligible and ineligible groups.

Keyphrases

phase iii
study protocol
phase ii
clinical trial
squamous cell carcinoma
small cell lung cancer
randomized controlled trial
open label
locally advanced
radiation therapy
liver metastases
placebo controlled